Key Takeaways
- Steady quarter, margin-led beat: Revenue grew 11% YoY to INR1,065 crore while gross margin expanded 200 bps to 69.1%, lifting EBITDA margin 60 bps to 28.7% on favorable mix and cost optimization.
- Domestic franchise stays ahead of the market: India business grew 10%, keeping the company as the fastest-growing top-25 player per IQVIA, though acute gastro products shaved ~1-1.5pp off the pace.
- International formulations delivered the upside surprise: 20% YoY growth to INR306 crore, powered by strong order-book execution in Russia, South Africa and branded export markets.
- CDMO held its ground against a tough base: Revenue was nearly flat at INR117 crore, sustaining momentum; management expects 10-12% growth in FY27.
- What to watch next quarter: Whether the Torrent merger deal closes in Q4 as signaled, the pace of ophthalmology’s ramp toward the INR17-18 crore monthly run rate, and any dividend decision after the pause in the interim payout.
Domestic Business: Chronic Strength, Acute Softness
- Chronic portfolio led the quarter: The chronic book did “exceedingly well,” with key brands outperforming the IPM, keeping the company on track to grow 200-300 bps above market for the nine-month period.
- Acute gastro caused the 1-1.5pp drag: Management attributed the gap between the ~10% print and the 11-12% run rate entirely to a slowdown in the acute business, specifically the gastro portfolio, and called it no real concern.
- Ophthalmology growing double digits: The chronic and glaucoma segments drove performance; a near-term monthly run rate of INR17-18 crore is expected within 3-4 months, with some softness confined to acute ophthalmic products.
- March seasonality flagged: Distributor inventory closing typically makes March a soft month for domestic pharma, so the quarterly run rate can be impacted.
Kunal Khanna: “No. So no real concern with the overall growth for domestic business. Our chronic portfolio has done exceedingly well. And the 1%, 1.5% difference, which we are seeing, instead of that 11% to 12%, being closer to 10% is largely attributed to some slowdown for our acute business, more specifically the gastro portfolio.”
International Formulations: Order-Book Execution Drove the Beat
- 20% growth on strong subsidiary performance: International formulations reached INR306 crore, driven by good demand and volume in both subsidiaries, South Africa and Russia, plus branded export markets.
- Order book visibility supports Q4: Management cited a good order book entering Q4 and expects double-digit growth for the quarter, taking the full year to high single digits.
- USA contributed to the quarter: The US market was listed among the growth drivers for international formulations alongside Russia, South Africa and other branded export markets.
CDMO: Flat Against a High Base, Growth Ahead
- Revenue nearly flat at INR117 crore: The CDMO business sustained sales momentum despite a high base in Q3 FY25, maintaining a quarterly run rate of INR115-120 crore.
- FY27 growth pegged at 10-12%: Management expects the CDMO segment to grow at that pace next fiscal year, signaling confidence in the order pipeline beyond the current base effect.
Nikhil Chopra: “Our run rate for the quarter -- for every quarter continues to be around INR115 crore to INR120 crore for this year. And you should expect us to grow at around 10% to 12% for FY '27.”
Margins: Mix and Efficiency Drove the Expansion
- Gross margin up 200 bps to 69.1%: The expansion came from an attractive product mix, with a higher contribution from the chronic portfolio in India, CDMO mix, geography mix, realized price improvement, and stable raw material costs.
- EBITDA margin improved 60 bps to 28.7%: Operating leverage from cost optimization and operational efficiencies added to the gross-margin tailwind, keeping the company within its 27-29% guided band.
- Q4 gross margin target of 68-69%: Management expects to reach that level by year-end, implying the favorable mix dynamics persist.
- Other income rose on surplus cash: With all debt now repaid, surplus cash invested per treasury policy generated higher treasury income, a tailwind below the operating line.
- Labour code impact was immaterial: Necessary impacts were taken in the P&L but were not substantial enough to call out.
Merger & Capital Allocation: Torrent Deal in Q4, Dividend Paused
- Torrent merger deal closure expected in Q4: Management described the process as “work in progress, progressing at normal speed” and said the deal may close sometime in the fourth quarter, with the merger itself taking 6-9 months from closure.
- No synergy commentary offered: When asked about possible merger synergies, management declined to comment, and similarly deflected a question on the 6-9 month timeline between deal closure and merger completion.
- Interim dividend skipped, policy unchanged: The company did not declare an interim dividend with these results, breaking a five-year pattern. Management said a dividend “will happen over time” and it will update when a decision is taken, but offered no specific timeline or rationale.
- Debt fully repaid: All outstanding debt has been cleared, leaving the balance sheet debt-free and generating surplus cash.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Operating margin | 27% to 29% band | FY26 |
| Gross margin | Reach 68% to 69% | By FY26 year-end |
| Domestic growth | 200-300 bps above IPM market growth | Ongoing; Q4 FY26 |
| International business growth | High single digit | Full year FY26 |
| CDMO growth | 10% to 12% | FY27 |
| Ophthalmology monthly run rate | INR17-18 crore | Next 3-4 months |
| Torrent merger deal closure | Deal closure expected | Q4 FY26 |
Key Metrics
| Metric | Q3 FY26 |
|---|---|
| Revenue | ₹1,065 crore, up 11% YoY |
| Domestic revenue | ₹620 crore, up 10% YoY |
| International revenue | ₹445 crore, up 12% YoY |
| International formulations revenue | ₹306 crore, up 20% YoY |
| CDMO revenue | ₹117 crore, nearly flat YoY |
| API revenue | ₹21 crore |
| Domestic franchisee revenue | ₹108 crore, up 11% YoY |
| Gross margin | 69.1%, up 200 bps YoY from 67.1% |
| Operating EBITDA (excl. ESOP) | ₹305 crore, up 13% YoY |
| Operating EBITDA margin | 28.7%, up 60 bps YoY from 28.1% |
| Net profit | ₹198 crore, up 22% YoY |
| Other income | ₹18 crore, up from ₹8 crore in Q3 FY25 due to treasury income |
| Depreciation | ₹45 crore, up from ₹42 crore in Q3 FY25 |
| Domestic price hike | ~7% for the quarter |
| Company IPM growth (IQVIA MAT Dec 2025) | 12%, versus IPM growth of 9% |
| CDMO quarterly run rate | ₹115 crore to ₹120 crore for FY26 |
| CDMO FY27 growth expectation | 10% to 12% |
| Ophthalmology portfolio monthly run rate aspiration | ₹17 crore to ₹18 crore, expected in next 3 to 4 months |
| ESOP charge if change of control occurs in Q4 | ~₹40 crore balance to be charged in Q4 |
| Operating margin guidance for FY26 | 27% to 29%, reiterated |
| India business Q4 FY26 growth guidance | 200 to 300 bps above market growth |
| Gross margin guidance for Q4 FY26 | 60% to 69% by year-end |